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Editorial
Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean 
patients with multiple myeloma?
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Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea
Multiple myeloma (MM) is a malignant hematological neo-
plasia of plasma cells. The clinical manifestations of MM 
are heterogeneous and include monoclonal immunoglobulin 
production, hypogammaglobulinemia, impaired hematopoi-
esis, osteolytic bone disease, hypercalcemia, and renal dy-
sfunction. Recently, novel agents such as thalidomide, lena-
lidomide, and bortezomib were introduced for the treatment 
of MM; treatment with these agents can effectively control 
both relapsed and newly diagnosed diseases and thereby 
improve survival.
  Patients with MM show heterogeneous outcomes, which 
range from a relatively indolent course with a lengthy sur-
vival period to a more aggressive disease course with dismal 
prognosis. Therefore, identification of these subgroups of 
patients has great clinical significance. Several factors related 
to the disease or the patient’s status have been shown to 
influence the disease course in MM. The Durie-Salmon stag-
ing system was previously used for clinical staging, and 
currently, the International Staging System (ISS), which 
uses laboratory factors such as serum albumin and beta- 
2-microglobulin levels, is commonly applied as a tool for 
standardized risk assessment [1]. Recently, new genetic risk 
stratifications have been proposed by several groups. The 
Mayo stratification, which is based on the results of plasma 
cell fluorescence in situ hybridization (FISH), metaphase 
cytogenetics, and plasma cell labeling index (PCLI), is a 
commonly cited representative system; the developers of 
this system have framed the mSMART (Mayo Stratification 
of Myeloma and Risk-Adapted Therapy) consensus guideline 
as a risk-adapted approach [2]. In the risk stratification, 
the high-risk group shows del17p, t(4;14), and t(14;16) in 
FISH, deletion 13 and hypodiploidy in metaphase cytoge-
netics, and PCLI ≥3%. Flow cytometric analysis of im-
munophenotypic markers such as CD19, CD27, CD28, CD45, 
CD56, and CD117 has become a useful tool for the diagnosis 
and monitoring of disease in cases of monoclonal gammo-
pathies [3]. Some biological parameters related to myeloma 
cells, such as hepatocyte growth factor (HGF), vascular en-
dothelial growth factor (VEGF), intercellular carboxy-ter-
minal telopeptide of type I collagen (ICTP), procollagen 
type I N-terminal propeptide (PINP), osteoprotegerin 
(OPG), and syndecan-1/CD138, have also been reported 
to play some roles in the diagnosis, staging, and prognosis 
of MM [4]. 
  Syndecan-1 (CD138) is a transmembrane heparan sul-
fate-bearing proteoglycan expressed on the surface of both 
normal and malignant plasma cells; this molecule regulates 
the adhesion, migration, and growth of myeloma cells. 
Syndecan-1 is actively shed from the surface of myeloma 
cells into human plasma. In an in vivo model, soluble synde-
can-1 is known to actively promote growth and dissem-
ination of myelomas [5]. Clinically, the serum level of synde-
can-1 is correlated with a high percentage of plasma cells 
in the bone marrow, disease stage, and serum M-component 
concentration; therefore, soluble syndecan-1 level has been 
shown to be an independent prognostic factor in myeloma 
[6]. Syndecan-1 expression has been known to be an im-
portant prognostic factor in other tumors [7].
  Kim et al. [8] analyzed soluble syndecan-1 levels in Korean 
patients with MM at the time of diagnosis and during therapy 
to evaluate the effect of soluble syndecan-1 on the ther-
apeutic response and prognosis. Because the annual in-Korean J Hematol 2010;45:143-4.
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cidence of MM in Korea has increased steadily by 30 times 
over the past 30 years, MM has become one of the major 
hematologic disorders in Korea, and the study performed 
by Kim et al. may have additional significance in the light 
of the epidemic aspect in Korea [9]. Although the median 
level of soluble syndecan-1 in patients with MM was higher 
than that in normal controls, the sensitivity of soluble synde-
can-1 levels in indicating MM was 75%. Kim et al. suggested 
that soluble syndecan-1 does not have adequate diagnostic 
value in Korean patients with MM. Consistent with the 
previous reports, soluble syndecan-1 levels correlated with 
disease stage, percentage of plasma cells in the bone marrow, 
β2-microglobulin level, serum M-component concentra-
tion, and creatinine level. High soluble syndecan-1 levels 
were associated with poor survival in the patients, although 
the association did not show any statistical significance. 
The major reason for the absence of significance in Korean 
patients with MM was the limited number of patients en-
rolled in that study. However, Kim et al. suggested that 
soluble syndecan-1 was a feasible prognostic factor in Korean 
patients with MM, as in the case of Western patients [6]. 
  Although the ISS is commonly used for clinical staging 
in patients with MM, several groups have tried to develop 
better prognostic factors that include the cytogenetic and 
FISH findings, the levels of biologic markers, and the results 
of gene-expression profiling. Among these, the representa-
tive tailed models for MM are microarray-based predictive 
models that use the gene expression data in Arkansas and 
the mSMART consensus guideline, which is a risk-adapted 
approach based on the Mayo stratification [2, 10]. Large- 
scale multicenter studies will be required to identify the 
prognostic model that is most suitable for predicting better 
clinical outcomes in the Korean patients. 
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